Brigitte Bressac-de Paillerets

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7298249/publications.pdf

Version: 2024-02-01

147 papers	14,561 citations	22099 59 h-index	19690 117 g-index
157 all docs	157 docs citations	157 times ranked	16996 citing authors

#	Article	IF	Citations
1	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 1991, 350, 429-431.	13.7	1,356
2	p53 functions as a cell cycle control protein in osteosarcomas.. Molecular and Cellular Biology, 1990, 10, 5772-5781.	1.1	779
3	Genetic Testing in Pheochromocytoma or Functional Paraganglioma. Journal of Clinical Oncology, 2005, 23, 8812-8818.	0.8	612
4	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. Journal of Clinical Oncology, 2015, 33, 2345-2352.	0.8	525
5	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
6	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, 94-98.	13.7	466
7	Geographical Variation in the Penetrance of CDKN2A Mutations for Melanoma. Journal of the National Cancer Institute, 2002, 94, 894-903.	3.0	435
8	Genome-wide association study identifies three loci associated with melanoma risk. Nature Genetics, 2009, 41, 920-925.	9.4	422
9	Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1973-1977.	3.3	386
10	High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL. Cancer Research, 2006, 66, 9818-9828.	0.4	373
11	Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]. Human Molecular Genetics, 1998, 7, 209-216.	1.4	345
12	2009 Version of the Chompret Criteria for Li Fraumeni Syndrome. Journal of Clinical Oncology, 2009, 27, e108-e109.	0.8	291
13	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
14	Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nature Genetics, 2014, 46, 482-486.	9.4	283
15	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
16	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. American Journal of Human Genetics, 2013, 92, 974-980.	2.6	239
17	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	9.4	230
18	Senescent cells develop a PARP-1 and nuclear factor-Î¹B-associated secretome (PNAS). Genes and Development, 2011, 25, 1245-1261.	2.7	223

#	Article	IF	Citations
19	PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology, 2004, 126, 318-321.	0.6	220
20	Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Human Mutation, 2012, 33, 1228-1238.	1.1	210
21	Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. Journal of Medical Genetics, 2008, 45, 535-538.	1.5	181
22	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	3.0	164
23	Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature Genetics, 2012, 44, 323-327.	9.4	160
24	Selection criteria for genetic assessment of patients with familial melanoma. Journal of the American Academy of Dermatology, 2009, 61, 677.e1-677.e14.	0.6	154
25	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 2011, 43, 1114-1118.	9.4	140
26	Cancer risk in heterozygotes for ataxia-telangiectasia. International Journal of Cancer, 2001, 93, 288-293.	2.3	124
27	Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene, 1998, 16, 1603-1610.	2.6	123
28	Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science Translational Medicine, 2015, 7, 283ra55.	5.8	120
29	The Founder Mutation MSH2*1906Gâ†'C Is an Important Cause of Hereditary Nonpolyposis Colorectal Cancer in the Ashkenazi Jewish Population. American Journal of Human Genetics, 2002, 71, 1395-1412.	2.6	118
30	Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. Journal of Medical Genetics, 2011, 48, 226-234.	1.5	116
31	Localization of a Novel Melanoma Susceptibility Locus to 1p22. American Journal of Human Genetics, 2003, 73, 301-313.	2.6	113
32	Melanoma prone families withCDK4germline mutation: phenotypic profile and associations withMC1Rvariants. Journal of Medical Genetics, 2013, 50, 264-270.	1.5	112
33	Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study. Journal of the National Cancer Institute, 2010, 102, 1568-1583.	3.0	108
34	Genetic testing for melanoma. Lancet Oncology, The, 2002, 3, 653-654.	5.1	106
35	High Frequency of Germline SUFU Mutations in Children With Desmoplastic/Nodular Medulloblastoma Younger Than 3 Years of Age. Journal of Clinical Oncology, 2012, 30, 2087-2093.	0.8	106
36	Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French <scp>FH</scp> mutation carriers. Clinical Genetics, 2017, 92, 606-615.	1.0	103

#	Article	IF	Citations
37	Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. British Journal of Cancer, 1999, 80, 1042-1045.	2.9	102
38	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. American Journal of Human Genetics, 2000, 67, 207-212.	2.6	100
39	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
40	Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Human Molecular Genetics, 1994, 3, 2257-2260.	1.4	98
41	Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families. Journal of the National Cancer Institute, 2004, 96, 785-795.	3.0	97
42	Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. British Journal of Cancer, 1996, 74, 537-545.	2.9	95
43	Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families. Cancer Research, 2004, 64, 8143-8147.	0.4	94
44	Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. European Journal of Immunology, 1995, 25, 1765-1769.	1.6	90
45	Germline <scp>BAP1</scp> mutations predispose also to multiple basal cell carcinomas. Clinical Genetics, 2015, 88, 273-277.	1.0	85
46	A Single Genetic Origin for the G101W CDKN2A Mutation in 20 Melanoma-Prone Families. American Journal of Human Genetics, 2000, 67, 311-319.	2.6	80
47	Prevalence of the <scp>E</scp>318<scp>K MITF</scp> germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell and Melanoma Research, 2013, 26, 259-262.	1.5	80
48	Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene, 1997, 15, 2817-2826.	2.6	78
49	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
50	Contribution of de novo and mosaic TP53 mutations to Li-Fraumeni syndrome. Journal of Medical Genetics, 2018, 55, 173-180.	1.5	78
51	Extensive molecular screening for hereditary non-polyposis colorectal cancer. British Journal of Cancer, 2000, 82, 871-880.	2.9	73
52	Screening for TP53 rearrangements in families with the Liâ€“Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene, 2003, 22, 840-846.	2.6	72
53	Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. Nucleic Acids Research, 2018, 46, 7913-7923.	6.5	71
54	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	0.6	70

#	Article	IF	Citations
55	Mutations in BHD and TP53 genes, but not in HNF1Î² gene, in a large series of sporadic chromophobe renal cell carcinoma. British Journal of Cancer, 2007, 96, 336-340.	2.9	65
56	Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Modern Pathology, 2018, 31, 974-983.	2.9	65
57	Melanocortin-1 Receptor (MC1R) Gene Variants and Dysplastic Nevi Modify Penetrance of CDKN2A Mutations in French Melanoma-Prone Pedigrees. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2384-2390.	1.1	64
58	Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN. Clinical Cancer Research, 2008, 14, 5925-5930.	3.2	64
59	Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect. Genes Chromosomes and Cancer, 2001, 32, 195-202.	1.5	63
60	Testing for BRCA1 mutations: a cost-effectiveness analysis. European Journal of Human Genetics, 2002, 10, 599-606.	1.4	58
61	BRCA Share: A Collection of Clinical BRCA Gene Variants. Human Mutation, 2016, 37, 1318-1328.	1.1	57
62	PARKINInactivation Links Parkinsonâ€™s Disease to Melanoma. Journal of the National Cancer Institute, 2016, 108, djv340.	3.0	56
63	Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro-Oncology, 2018, 20, 1122-1132.	0.6	52
64	BRAF as a melanoma susceptibility candidate gene?. Cancer Research, 2003, 63, 3061-5.	0.4	52
65	Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. Journal of Medical Genetics, 2010, 47, 142-144.	1.5	51
66	Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. Journal of Medical Genetics, 2005, 43, 39-47.	1.5	50
67	Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica, 2012, 97, 9-14.	1.7	50
68	Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. British Journal of Cancer, 2000, 82, 818-822.	2.9	47
69	Genetic and environmental factors in cutaneous malignant melanoma. Biochimie, 2002, 84, 67-74.	1.3	47
70	Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Molecular Oncology, 2008, 1, 425-430.	2.1	47
71	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
72	Cutaneous phenotype andMC1R variants as modifying factors for the development of melanoma inCDKN2A G101W mutation carriers from 4 countries. International Journal of Cancer, 2007, 121, 825-831.	2.3	45

#	Article	IF	Citations
73	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. European Journal of Human Genetics, 2018, 26, 1732-1742.	1.4	44
74	p53 STATUS DOES NOT PREDICT INITIAL CLINICAL RESPONSE TO BACILLUS CALMETTE-GUERIN INTRAVESICAL THERAPY IN T1 BLADDER TUMORS. Journal of Urology, 1998, 159, 1079-1084.	0.2	43
75	Real-time PCR-based gene dosage assay for detecting BRCA1 rearrangements in breast-ovarian cancer families. Clinical Genetics, 2004, 65, 131-136.	1.0	42
76	Correlation betweenp53 gene expression and tumor-cell proliferation in oropharyngeal cancer. International Journal of Cancer, 1994, 57, 458-462.	2.3	41
77	Functional, structural, and genetic evaluation of 20CDKN2Agerm line mutations identified in melanoma-prone families or patients. Human Mutation, 2009, 30, 564-574.	1.1	38
78	A germline mutation inPBRM1predisposes to renal cell carcinoma. Journal of Medical Genetics, 2015, 52, 426-430.	1.5	38
79	BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Familial Cancer, 2007, 6, 453-461.	0.9	36
80	Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. Breast Cancer Research and Treatment, 2013, 141, 135-144.	1.1	35
81	Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. European Journal of Immunology, 1995, 25, 1638-1642.	1.6	34
82	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma. JAMA Dermatology, 2019, 155, 604.	2.0	34
83	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
84	Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research, 2014, 74, 6554-6564.	0.4	32
85	CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes and Cancer, 2003, 38, 265-268.	1.5	31
86	Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro. European Journal of Endocrinology, 2010, 162, 771-777.	1.9	28
87	Tracking of Second Primary Melanomas in Vemurafenib-Treated Patients. JAMA Dermatology, 2013, 149, 488.	2.0	28
88	A germline oncogenic MITF mutation and tumor susceptibility. European Journal of Cell Biology, 2014, 93, 71-75.	1.6	28
89	IMPACT OF GENE PATENTS ON THE COST-EFFECTIVE DELIVERY OF CARE: THE CASE OF BRCA1 GENETIC TESTING. International Journal of Technology Assessment in Health Care, 2003, 19, 287-300.	0.2	27
90	Breast cancer risk inBRCA1 andBRCA2 mutation carriers and polyglutamine repeat length in theAIB1 gene. International Journal of Cancer, 2005, 117, 230-233.	2.3	27

#	Article	IF	Citations
91	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Research and Treatment, 2011, 127, 671-679.	1.1	27
92	Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression. Journal of the National Cancer Institute, 2017, 109, .	3.0	27
93	Familial melanoma: Clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. Journal of the American Academy of Dermatology, 2012, 67, 1257-1264.e2.	0.6	26
94	The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. British Journal of Cancer, 2008, 99, 364-370.	2.9	25
95	A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. European Journal of Human Genetics, 2003, 11, 288-296.	1.4	24
96	Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics, 2014, 15, 487.	1.2	24
97	Melanoma Risk and Melanocyte Biology. Acta Dermato-Venereologica, 2020, 100, adv00139.	0.6	24
98	Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. Acta Neuropathologica, 2015, 129, 921-923.	3.9	23
99	Structure-activity relationships in glucocorticoid-induced apoptosis in T lymphocytes. Biochemical Pharmacology, 1995, 50, 103-110.	2.0	22
100	Contribution of CDKN2A/P16 INK4A, P14 ARF, CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Familial Cancer, 2010, 9, 663-667.	0.9	22
101	Characteristics, Treatment, and Outcome of Breast Cancers Diagnosed in BRCA1 and BRCA2 Gene Mutation Carriers in Intensive Screening Programs Including Magnetic Resonance Imaging. Clinical Breast Cancer, 2010, 10, 113-118.	1.1	22
102	Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer, 2010, 116, 5716-5724.	2.0	22
103	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
104	Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. Journal of Endocrinology, 2003, 178, 301-310.	1.2	21
105	Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk. Molecular Cancer Research, 2019, 17, 54-69.	1.5	21
106	GermlineCDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. Journal of Medical Genetics, 2017, 54, 607-612.	1.5	19
107	Genetic transmission of susceptibility to cancer in families of children with soft tissue sarcomas. , 1996, 78, 1483-1491.		18
108	Patterns of familial aggregation of three melanoma risk factors: great number of naevi, light phototype and high degree of sun exposure. International Journal of Epidemiology, 2000, 29, 408-415.	0.9	18

#	Article	IF	Citations
109	Soft Tissue Sarcomas. Journal of Clinical Oncology, 2004, 22, 2029-2031.	0.8	18
110	Diversity of the clinical presentation of the MMR gene biallelic mutations. Familial Cancer, 2014, 13, 131-135.	0.9	18
111	Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1â€expression: A pilot study. Genes Chromosomes and Cancer, 2017, 56, 691-694.	1.5	18
112	Germline Variation at CDKN2A and Associations with Nevus Phenotypes amongÂMembers of Melanoma Families. Journal of Investigative Dermatology, 2017, 137, 2606-2612.	0.3	18
113	Response to systemic therapy in fumarate hydrataseâ€“deficient renal cell carcinoma. European Journal of Cancer, 2021, 151, 106-114.	1.3	18
114	Factors Associated with Altered Long-Term Well-Being After Prophylactic Salpingo-Oophorectomy Among Women at Increased Hereditary Risk for Breast and Ovarian Cancer. Oncologist, 2011, 16, 1250-1257.	1.9	17
115	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. European Journal of Human Genetics, 2016, 24, 99-105.	1.4	17
116	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology, 2019, 81, 386-394.	0.6	17
117	FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells. Cell Death and Differentiation, 2021, 28, 1837-1848.	5.0	17
118	The 5â€²-untranslated region of p16INK4a melanoma tumor suppressor acts as a cellular IRES, controlling mRNA translation under hypoxia through YBX1 binding. Oncotarget, 2015, 6, 39980-39994.	0.8	17
119	The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4764-4768.	1.8	16
120	Optimization of Next-Generation Sequencing Technologies for von Hippel Lindau (VHL) Mosaic Mutation Detection and Development of Confirmation Methods. Journal of Molecular Diagnostics, 2019, 21, 462-470.	1.2	16
121	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
122	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
123	eMelanoBase: An online locus-specific variant database for familial melanoma. Human Mutation, 2003, 21, 2-7.	1.1	15
124	Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families. British Journal of Dermatology, 2013, 169, 594-599.	1.4	15
125	Multiple skin hamartomata: a possible novel clinical presentation of SUFU neoplasia syndrome. Familial Cancer, 2015, 14, 151-155.	0.9	15
126	GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, 490.	1.3	14

#	Article	IF	Citations
127	Absence of microsatellite instability in thyroid carcinomas. European Journal of Cancer, 1995, 31, 128.	1.3	13
128	Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours. British Journal of Cancer, 2005, 92, 2278-2285.	2.9	13
129	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofÂMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069.	0.3	13
130	Hereditary breast cancer associated with a germline BRCA2 mutation in identical female twins with similar disease expression. Cancer Genetics and Cytogenetics, 2002, 133, 24-28.	1.0	12
131	New founder germline mutations ofCDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment. Genes Chromosomes and Cancer, 2007, 46, 751-760.	1.5	12
132	Germline mutations in the new E1â€™ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	1.5	12
133	Germline Mutations of Inhibins in Earlyâ€Onset Ovarian Epithelial Tumors. Human Mutation, 2014, 35, 294-297.	1.1	11
134	Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes. Familial Cancer, 2009, 8, 371-377.	0.9	10
135	Absence of somatic alterations of the EB1 gene adenomatous polyposis coli-associated protein in human sporadic colorectal cancers. British Journal of Cancer, 1998, 78, 1356-1360.	2.9	9
136	Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. Melanoma Research, 2001, 11, 117-122.	0.6	9
137	The <scp>CDKN</scp>2A/p16<scp>^{INK}</scp>^{4a} 5â€²<scp>UTR</scp> sequence and translational regulation: impact of novel variants predisposing to melanoma. Pigment Cell and Melanoma Research, 2016, 29, 210-221.	1.5	9
138	Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. International Journal of Oncology, 2018, 53, 1455-1468.	1.4	9
139	Non-Hodgkinâ€™s lymphomas and myeloid disorders: deletions associated with t(2;5) and t(3;5) detected by FISH. Leukemia, 1998, 12, 1159-1162.	3.3	8
140	NovelFHmutation in a patient with cutaneous leiomyomatosis associated with cutis verticis gyrata, eruptive collagenoma and Charcot-Marie-Tooth disease. British Journal of Dermatology, 2010, 163, 1337-1339.	1.4	8
141	Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I. Human Mutation, 2022, 43, 316-327.	1.1	8
142	Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence. JAMA Dermatology, 2017, 153, 1122.	2.0	7
143	Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors. Cancer Genetics, 2021, 258-259, 51-56.	0.2	5
144	Genetic Testing for Melanomaâ€”Where Are We With Moderate-Penetrance Genes?. JAMA Dermatology, 2016, 152, 375.	2.0	2

#	Article	IF	Citations
145	The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma. Cancers, 2021, 13, 2243.	1.7	2
146	Is Systemic Disease in the Coelomic Epithelium Associated With BRCA1 Germline Mutations?. Journal of the National Cancer Institute, 2004, 96, 488-489.	3.0	1
147	Prise en charge des formes familiales de tumeurs rares : mÃ©lanomes familiaux et primitifs multiples. Oncologie, 2008, 10, 411-414.	0.2	0